Key terms

About OTLK

Outlook Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of ONS-5010/LYTENAVA. Its pipeline includes unmet patient needs, repackaged IV bevacizumab, and anti-VEGF. The company was founded by Pankaj Mohan on January 5, 2010 and is headquartered in Iselin, NJ.

Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
     
52-week range
     
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date

Key terms

Smart score

Latest OTLK news

Mar 28 5:04pm ET Outlook Therapeutics files $300M mixed securities shelf by TipRanks Mar 27 9:47am ET Spotify initiated, Lowe’s downgraded: Wall Street’s top analyst calls by TipRanks Mar 27 6:35am ET Outlook Therapeutics upgraded to Buy from Neutral at BTIG by TipRanks Mar 26 4:33pm ET Outlook Therapeutics Grants Stock Options to Top Executives by TipRanks Mar 25 4:13pm ET Outlook Therapeutics files to sell 21.43M shares of common stock for holders by TipRanks Mar 25 8:35am ET Outlook Therapeutics: Buy Rating Affirmed Amid Positive European Developments and Anticipated U.S. Market Success by TipRanks Mar 24 10:45pm ET Buy Rating Affirmed for Outlook Therapeutics: European Endorsement and Pivotal US Study Progress Signal Strong Market Potential by TipRanks Mar 22 9:35am ET Outlook Therapeutics Inc trading resumes by TipRanks Mar 22 9:30am ET Outlook Therapeutics Inc trading halted, volatility trading pause by TipRanks Mar 22 7:38am ET Outlook Therapeutics announces CHMP of EMA issued positive opinion on ONS-5010 by TipRanks Mar 18 11:45pm ET Buy Rating Affirmed for Outlook Therapeutics Amidst Strong Financial Positioning and Advancing Clinical Trials by TipRanks Mar 18 11:03am ET Biotech Alert: Searches spiking for these stocks today by TipRanks Mar 15 10:11am ET Outlook Therapeutics Inc trading resumes by TipRanks Mar 15 10:06am ET Outlook Therapeutics Inc trading halted, volatility trading pause by TipRanks Mar 13 7:50pm ET Outlook Therapeutics Inc trading halted, news pending by TipRanks Mar 12 8:23am ET Outlook Therapeutics announces effective date for 1-for-20 reverse stock split by TipRanks Feb 16 8:15am ET Buy Rating Affirmed for Outlook Therapeutics Amidst Promising Market Prospects for ONS-5010/Lytenava by TipRanks Feb 15 7:14am ET Outlook Therapeutics upgraded to Buy from Neutral at Chardan by TipRanks Feb 15 6:27am ET Buy Rating Affirmed for Outlook Therapeutics on Strategic Progress and Strong Financial Positioning by TipRanks Feb 15 6:14am ET Outlook Therapeutics price target lowered to $1.50 from $2 at H.C. Wainwright by TipRanks Feb 14 8:08am ET Outlook Therapeutics reports Q1 EPS (4c), consensus (5c) by TipRanks Jan 31 8:12am ET Outlook Therapeutics doses first subject in NORSE EIGHT trial by TipRanks Jan 26 11:25am ET Biotech Alert: Searches spiking for these stocks today by TipRanks Jan 25 11:38am ET Biotech Alert: Searches spiking for these stocks today by TipRanks Jan 25 11:38am ET Biotech Alert: Searches spiking for these stocks today by TipRanks Jan 25 6:21am ET Outlook Therapeutics upgraded to Buy from Neutral at Guggenheim by TipRanks Jan 25 5:35am ET Wall Street Analysts Are Bullish on Top Healthcare Picks by TipRanks Jan 25 5:18am ET Outlook Therapeutics upgraded to Buy from Hold at Brookline by TipRanks Jan 25 4:01am ET Outlook Therapeutics Announces Private Placement and Note Amendment by TipRanks Jan 25 4:01am ET Outlook Therapeutics Executes Unregistered Equity Sales by TipRanks Jan 25 4:01am ET Outlook Therapeutics Incurs New Financial Obligations by TipRanks

No recent press releases are available for OTLK

OTLK Financials

1-year income & revenue

Key terms

OTLK Forecasts

analyst rating

  • buy
  • hold
  • sell

We're sorry, but this
information is
temporarily unavailable.

1-year stock price forecast

OTLK Competitors

$ Market cap P/E ratio $ Price 1d change 52-week range

Key terms

Latest investing news

Trump Media, which runs the social media platform Truth Social, took the place of Digital World's place on the Nasdaq stock exchange in March.
Frank Franklin II/AP
Trump Media stock ends session 15% higher after two very bad days
Students at Highlands High School, work on a practice test at the ACT Boot Camp in Newport, Ky.
Patrick Reddy/The Enquirer/AP/File
Private equity finds its next bet: college admissions
In this photo illustration, Republican presidential candidate former President Donald Trump's social media platform Truth Social is shown on a cell phone on March 25, 2024 in Chicago, Illinois.
Scott Olson/Getty Images
Trump’s stock tumbles again after Truth Social announces it’s getting into streaming
Tim Wren, chief commercial officer for BSI Group, right, presents Kristalina Georgieva, chief executive officer of the World Bank Group, second right, with ISO 20121 certification for sustainable event management at an event during the spring meetings of the International Monetary Fund (IMF) and World Bank in Washington, DC, US, on Monday, April 15, 2024. The IMF and World Bank spring meetings in Washington are expected to draw thousands of delegates, observers and journalists from the fund's 190 member countries. Photographer: Samuel Corum/Bloomberg via Getty Images
Samuel Corum/Bloomberg/Getty Images
Geopolitical strife is roiling Wall Street. Here’s what investors are watching